CY2019004I1 - Τροποποιημενα αντισωματα αντι-ιl-23ρ19 - Google Patents

Τροποποιημενα αντισωματα αντι-ιl-23ρ19

Info

Publication number: CY2019004I1
Authority: CY; Cyprus
Prior art keywords: antibodies; modified anti; modified
Prior art date: 2007-02-23

Application number

CY2019004C

Other languages

English (en)

Other versions

CY2019004I2 (el

Original Assignee

Merck Sharp & Dohme Corp.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-23

Filing date

2019-01-14

Publication date

2019-11-27

2019-01-14 Application filed by Merck Sharp & Dohme Corp. filed Critical Merck Sharp & Dohme Corp.

2019-11-27 Publication of CY2019004I1 publication Critical patent/CY2019004I1/el

2019-11-27 Publication of CY2019004I2 publication Critical patent/CY2019004I2/el

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Diabetes (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Toxicology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Endocrinology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Pulmonology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Obesity (AREA)
Orthopedic Medicine & Surgery (AREA)
Virology (AREA)
Ophthalmology & Optometry (AREA)

CY2019004C 2007-02-23 2019-01-14 Τροποποιημενα αντισωματα αντι-ιl-23ρ19 CY2019004I2 (el)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US89140907P	2007-02-23	2007-02-23
PCT/US2008/002333 WO2008103432A1 (en)	2007-02-23	2008-02-21	Engineered anti-il-23p19 antibodies

Publications (2)

Publication Number	Publication Date
CY2019004I1 true CY2019004I1 (el)	2019-11-27
CY2019004I2 CY2019004I2 (el)	2019-11-27

Family

ID=39592753

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
CY20121100644T CY1112912T1 (el)	2007-02-23	2012-07-20	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY2019004C CY2019004I2 (el)	2007-02-23	2019-01-14	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
CY20191100082T CY1121327T1 (el)	2007-02-23	2019-01-21	Τροποποιημενα αντισωματα anti-il-23p19

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
CY20121100644T CY1112912T1 (el)	2007-02-23	2012-07-20	Τροποποιημενα αντισωματα αντι-ιl-23ρ19

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
CY20191100082T CY1121327T1 (el)	2007-02-23	2019-01-21	Τροποποιημενα αντισωματα anti-il-23p19

Country Status (31)

Country	Link
US (3)	US8293883B2 (el)
EP (2)	EP2059534B1 (el)
JP (5)	JP2010518856A (el)
KR (1)	KR101520110B1 (el)
CN (1)	CN101687925B (el)
AR (1)	AR065420A1 (el)
AT (1)	ATE554791T1 (el)
AU (1)	AU2008218968B2 (el)
BR (1)	BRPI0807710B1 (el)
CA (1)	CA2678749C (el)
CY (3)	CY1112912T1 (el)
DK (2)	DK2426144T3 (el)
ES (2)	ES2708988T3 (el)
FR (1)	FR18C1051I2 (el)
HK (1)	HK1127864A1 (el)
HR (2)	HRP20120611T1 (el)
HU (2)	HUE042172T2 (el)
IL (1)	IL200560A (el)
LT (2)	LT2426144T (el)
LU (1)	LUC00092I2 (el)
MX (1)	MX2009009079A (el)
NL (1)	NL300959I2 (el)
NO (1)	NO2018040I1 (el)
NZ (1)	NZ579158A (el)
PL (2)	PL2426144T3 (el)
PT (2)	PT2059534E (el)
RS (2)	RS58098B1 (el)
SI (2)	SI2426144T1 (el)
TR (1)	TR201821029T4 (el)
WO (1)	WO2008103432A1 (el)
ZA (1)	ZA200906224B (el)

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SI2452694T1 (sl)	2005-06-30	2019-05-31	Janssen Biotech, Inc.	Protitelesa proti-IL-23, sestavki in postopki uporabe
US7910703B2 (en)	2006-03-10	2011-03-22	Zymogenetics, Inc.	Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
ES2568436T3 (es)	2006-03-31	2016-04-29	Chugai Seiyaku Kabushiki Kaisha	Procedimiento para controlar la farmacocinética en sangre de anticuerpos
PE20080333A1 (es)	2006-06-08	2008-06-15	Chugai Pharmaceutical Co Ltd	Agentes para prevenir o tratar enfermedades inflamatorias
JP2009540018A (ja)	2006-06-13	2009-11-19	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
TWI426918B (zh)	2007-02-12	2014-02-21	Merck Sharp & Dohme	Ｉｌ-２３拮抗劑於治療感染之用途
WO2008103473A1 (en)	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
CN101687925B (zh) *	2007-02-23	2012-10-31	先灵公司	抗IL-23p19的工程抗体
AU2008296361B2 (en)	2007-09-04	2013-04-11	Compugen, Ltd.	Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP3127921A1 (en)	2007-09-26	2017-02-08	Chugai Seiyaku Kabushiki Kaisha	Method of modifying isoelectric point of antibody via amino acid substition in cdr
CL2008002886A1 (es)	2007-09-26	2009-12-04	Chugai Pharmaceutical Co Ltd	Region constante de un anticuerpo humano; anticuerpo anti-receptor de interleucina-6 (il-6) y composicion farmaceutica que la comprende.
EP2241332A4 (en)	2007-12-05	2011-01-26	Chugai Pharmaceutical Co Ltd	THERAPEUTIC AGENT AGAINST PRITURE
BRPI0821110B8 (pt)	2007-12-05	2021-05-25	Chugai Pharmaceutical Co Ltd	anticorpo de neutralização de anti-nr10/il31ra, composição farmacêutica compreendendo o referido anticorpo e uso do mesmo
KR102269708B1 (ko)	2008-04-11	2021-06-25	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복 결합하는 항원 결합 분자
WO2010027766A1 (en)	2008-08-27	2010-03-11	Schering Corporation	Lyophilized formulatons of engineered anti-il-23p19 antibodies
JP2012507723A (ja) *	2008-11-03	2012-03-29	シェーリングコーポレイション	炎症性腸疾患生物マーカーおよび関連治療方法
KR20160062207A (ko) *	2008-12-05	2016-06-01	추가이 세이야쿠 가부시키가이샤	항ｎｒ１０ 항체 및 그의 이용
JP5139517B2 (ja) *	2008-12-05	2013-02-06	中外製薬株式会社	抗ｎｒ１０抗体、およびその利用
CA2745218A1 (en) *	2008-12-19	2010-06-24	Schering Corporation	Feed supplement for mammalian cell culture and methods of use
KR101048593B1 (ko)	2009-02-27	2011-07-12	씨제이제일제당 (주)	메칠머캅탄과 디메칠설파이드의 혼합물을 사용하여 메치오닌 생산능을 증가시키는 방법
KR101164711B1 (ko)	2009-02-27	2012-07-11	씨제이제일제당 (주)	미네랄 첨가와 산처리를 이용하여 메치오닌의 용해도를 증가시키는 방법
JP2010210772A (ja) *	2009-03-13	2010-09-24	Dainippon Screen Mfg Co Ltd	液晶表示装置の製造方法
WO2010107110A1 (ja)	2009-03-19	2010-09-23	中外製薬株式会社	抗体定常領域改変体
TWI544077B (zh)	2009-03-19	2016-08-01	Chugai Pharmaceutical Co Ltd	Antibody constant region change body
US20120269765A1 (en) *	2009-07-24	2012-10-25	Garcia K Christopher	Cytokine compositions and methods of use thereof
US8283152B2 (en)	2009-08-28	2012-10-09	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
US8609396B2 (en)	2009-08-28	2013-12-17	Cj Cheiljedang Corporation	Microorganism producing O-acetyl-homoserine and the method of producing O-acetyl-homoserine using the microorganism
WO2011033493A1 (en) *	2009-09-21	2011-03-24	Conservatoire National des Arts et Métiers	Carrier conjugates of il-23-peptides and their induced antibodies
JO3244B1 (ar)	2009-10-26	2018-03-08	Amgen Inc	بروتينات ربط مستضادات il – 23 البشرية
EA201270713A1 (ru) *	2010-02-18	2013-01-30	Бристол-Майерс Сквибб Компани	Белки на основе фибронектина с каркасными доменами, которые связывают ил-23
MX362039B (es)	2010-11-04	2019-01-07	Boehringer Ingelheim Int	Anticuerpos anti-il-23.
US20140234340A1 (en)	2010-11-30	2014-08-21	Chugai Seiyaku Kabushiki Kaisha	Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
WO2012093127A2 (en)	2011-01-04	2012-07-12	Universität Zürich	Modulators of il-12 and/or il-23 for the prevention or treatment of alzheimer's disease
WO2013001517A1 (en)	2011-06-30	2013-01-03	Compugen Ltd.	Polypeptides and uses thereof for treatment of autoimmune disorders and infection
EP2583979B1 (en) *	2011-10-19	2015-12-16	Effimune	Methods to prepare antibodies directed against p19 subunit of human IL-23
WO2013114367A2 (en)	2012-02-01	2013-08-08	Compugen Ltd.	C10rf32 antibodies, and uses thereof for treatment of cancer
NZ700802A (en) *	2012-05-03	2017-06-30	Boehringer Ingelheim Int	Anti-il-23p19 antibodies
ES2729603T3 (es) *	2012-06-27	2019-11-05	Merck Sharp & Dohme	Anticuerpos IL-23 antihumanos cristalinos
EP2920202B1 (en)	2012-11-19	2018-08-29	Pieris Pharmaceuticals GmbH	Novel specific-binding polypeptides and uses thereof
CZ2012829A3 (cs)	2012-11-23	2014-06-11	Biotechnologický Ústav Av Čr, V.V.I.	Polypeptidy pro léčbu autoimunitních chorob založenou na blokaci receptoru pro lidský cytokin IL-23
US20150307606A1 (en) *	2012-12-13	2015-10-29	Ashwin Basarkar	Lyophilized spherical pellets of anti-il-23 antibodies
UA117466C2 (uk) *	2012-12-13	2018-08-10	Мерк Шарп Енд Доме Корп.	СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh)	2013-03-08	2018-09-21	美國禮來大藥廠	結合ｉｌ－２３之抗體
AP2015008801A0 (en)	2013-03-15	2015-10-31	Amgen Inc	Methods for treating crohn's disease using an anti-il23 antibody
HRP20211911T1 (hr)	2013-03-15	2022-03-18	Protagonist Therapeutics, Inc.	Analozi hepcidina i njihova uporaba
SG11201507482UA (en)	2013-03-15	2015-10-29	Amgen Inc	Methods for treating psoriasis using an anti-il-23 antibody
SI3143037T1 (sl)	2014-05-16	2021-11-30	Protagonist Therapeutics, Inc.	Antagonisti integrin alpha4beta7 tioeterskih peptidov
CA3170782A1 (en)	2014-05-22	2015-11-26	Pieris Pharmaceuticals Gmbh	Novel specific-binding polypeptides and uses thereof
TWI713453B (zh)	2014-06-23	2020-12-21	美商健生生物科技公司	干擾素α及ω抗體拮抗劑
DK3169403T5 (da)	2014-07-17	2024-09-16	Protagonist Therapeutics Inc	Orale peptidinhibitorer af interleukin-23-receptor og deres anvendelse til behandling af inflammatoriske tarmsygdomme
WO2016014775A1 (en)	2014-07-24	2016-01-28	Boehringer Ingelheim International Gmbh	Biomarkers useful in the treatment of il-23a related diseases
UA122395C2 (uk) *	2014-08-19	2020-11-10	Мерк Шарп Енд Доум Корп.	Антитіло проти tigit
PE20171139A1 (es)	2014-09-03	2017-08-09	Boehringer Ingelheim Int	Compuesto dirigido a il-23a y tnf-alfa y sus usos
US9809623B2 (en)	2014-10-01	2017-11-07	Protagonist Therapeutics, Inc.	α4β7 peptide monomer and dimer antagonists
EP3201217A4 (en)	2014-10-01	2018-07-18	Protagonist Therapeutics Inc.	Novel cyclic monomer and dimer peptides having integrin antagonist activity
AR102417A1 (es)	2014-11-05	2017-03-01	Lilly Co Eli	Anticuerpos biespecíficos anti-tnf- / anti-il-23
MX2017010037A (es)	2015-02-04	2018-05-15	Boehringer Ingelheim Int	Metodos de tratamiento de enfermedades inflamatorias.
EP3685856A1 (en)	2015-04-14	2020-07-29	Boehringer Ingelheim International GmbH	Treatment of asthma with anti-il-23a antibodies
RU2749512C2 (ru)	2015-04-14	2021-06-11	Чугаи Сейяку Кабусики Кайся	Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента
US10787490B2 (en)	2015-07-15	2020-09-29	Protaganist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX2018003376A (es)	2015-09-17	2018-08-15	Amgen Inc	Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23.
TWI811716B (zh)	2015-09-18	2023-08-11	德商百靈佳殷格翰國際股份有限公司	治療發炎性疾病之方法
JP2019508370A (ja)	2015-12-22	2019-03-28	アムジェンインコーポレイテッド	Ｉｌ２３アンタゴニストに対する臨床応答の予測因子としてのｃｃｌ２０
WO2017117411A1 (en)	2015-12-30	2017-07-06	Protagonist Therapeutics, Inc.	Analogues of hepcidin mimetics with improved in vivo half lives
EP3432906A4 (en)	2016-03-23	2020-04-01	Protagonist Therapeutics, Inc.	METHOD FOR SYNTHETIZING ALPHA4BETA7 PEPTIDE ANTAGONISTS
AU2017250583A1 (en)	2016-04-15	2018-08-16	Boehringer Ingelheim International Gmbh	Methods of treating inflammatory diseases
AU2017343565A1 (en)	2016-10-10	2019-05-30	Cellerant Therapeutics, Inc.	Isoquinolidinobenzodiazepine (IQB)-1(chloromethyl)-2,3-dihydro-1H-benzo[e]indole (CBI) dimers
EP4032906A1 (en)	2016-10-14	2022-07-27	Boehringer Ingelheim International GmbH	Methods of treating diseases
JP7032394B2 (ja)	2016-10-16	2022-03-30	カンタージアアクチエボラーグ	抗ｉｌ１－ｒａｐ抗体
WO2018071910A2 (en) *	2016-10-16	2018-04-19	Cellerant Therapeutics, Inc.	Anti-il1-rap antibodies
SG11201909955XA (en)	2017-05-02	2019-11-28	Merck Sharp & Dohme	Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
JOP20190260A1 (ar)	2017-05-02	2019-10-31	Merck Sharp & Dohme	صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP4092038A1 (en)	2017-09-11	2022-11-23	Protagonist Therapeutics, Inc.	Opioid agonist peptides and uses thereof
WO2019157268A1 (en)	2018-02-08	2019-08-15	Protagonist Therapeutics, Inc.	Conjugated hepcidin mimetics
TWI837532B (zh)	2018-03-30	2024-04-01	美商美國禮來大藥廠	治療潰瘍性結腸炎之方法
CA3105598A1 (en)	2018-07-13	2020-01-16	Carl GOMMOLL	Treating ulcerative colitis with brazikumab
AU2019386021B2 (en) *	2018-11-27	2024-02-15	Innovent Biologics (Suzhou) Co., Ltd.	Anti-il-23p19 antibody and uses thereof
EP3952993B1 (en)	2019-04-12	2025-01-08	Almirall S.A.	Method of treating fumaric acid ester-resistant plaque psoriasis
EP3956357A4 (en) *	2019-04-15	2023-01-04	Sun Pharmaceutical Industries Limited	METHODS OF TREATMENT OF SUBJECTS WITH PSORIAL ARTHRITIS
AU2020311395A1 (en)	2019-07-10	2022-02-03	Protagonist Therapeutics, Inc.	Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP6845973B1 (ja)	2019-11-20	2021-03-24	中外製薬株式会社	抗体含有製剤
JP2023509373A (ja)	2019-12-20	2023-03-08	ノヴァロックバイオセラピューティクス，リミテッド	抗インターロイキン－２３ｐ１９抗体およびそれの使用方法
KR20220141808A (ko)	2020-01-15	2022-10-20	얀센 바이오테크 인코포레이티드	인터루킨-23 수용체의 펩티드 억제제 및 염증성 질환을 치료하기 위한 이의 용도
CN115298196A (zh)	2020-01-15	2022-11-04	詹森生物科技公司	介白素-23受体的肽抑制剂及其治疗炎性疾病的用途
KR102481026B1 (ko) *	2020-04-22	2022-12-22	한양대학교 산학협력단	인터루킨 23의 항체를 포함하는 화학요법유발 말초신경병증의 예방 또는 치료용 약학적 조성물
CN112807428B (zh) *	2020-06-12	2024-08-27	江苏荃信生物医药股份有限公司	包含抗人白介素23单克隆抗体的药物组合物
AR123477A1 (es)	2020-09-10	2022-12-07	Lilly Co Eli	Formulaciones de anticuerpos terapéuticos
TW202237167A (zh)	2020-11-20	2022-10-01	比利時商健生藥品公司	介白素-23受體之肽抑制劑組合物
CA3219846A1 (en)	2021-05-28	2022-12-01	Venkatesh Krishnan	Anti-il-23p19 antibody regulation of genes involved in ulcerative colitis
US20240391994A1 (en)	2021-09-30	2024-11-28	Eli Lilly And Company	Anti-il-23p19 antibody regulation of genes involved in bowel urgency in ulcerative colitis
US20240400670A1 (en) *	2021-09-30	2024-12-05	Jiangsu Hengrui Pharmaceuticals Co., Ltd.	Anti-il23 antibody fusion protein and uses thereof
EP4469154A1 (en)	2022-01-25	2024-12-04	Sun Pharmaceutical Industries Limited	Methods for treatment of subjects with plaque psoriasis of the scalp
WO2024077113A1 (en)	2022-10-06	2024-04-11	Eli Lilly And Company	Methods of treating fatigue in ulcerative colitis
WO2024178157A1 (en)	2023-02-22	2024-08-29	Eli Lilly And Company	Regulation of genes in ulcerative colitis and the uses thereof
US20240391993A1 (en) *	2023-05-25	2024-11-28	Sun Pharmaceutical Industries Limited	Methods and compositions for treating plaque psoriasis

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL154598B (nl)	1970-11-10	1977-09-15	Organon Nv	Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en)	1971-05-14	1974-06-18	Syva Corp	Enzyme amplification assay
US3939350A (en)	1974-04-29	1976-02-17	Board Of Trustees Of The Leland Stanford Junior University	Fluorescent immunoassay employing total reflection for activation
US3996345A (en)	1974-08-12	1976-12-07	Syva Company	Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en)	1978-04-05	1981-07-07	Syva Company	Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en)	1978-11-24	1981-06-23	Syva Company	Macromolecular environment control in specific receptor assays
US4366241A (en)	1980-08-07	1982-12-28	Syva Company	Concentrating zone method in heterogeneous immunoassays
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4683195A (en)	1986-01-30	1987-07-28	Cetus Corporation	Process for amplifying, detecting, and/or-cloning nucleic acid sequences
GB8607679D0 (en)	1986-03-27	1986-04-30	Winter G P	Recombinant dna product
DE3883899T3 (de)	1987-03-18	1999-04-22	Sb2, Inc., Danville, Calif.	Geänderte antikörper.
ES2052027T5 (es)	1988-11-11	2005-04-16	Medical Research Council	Clonacion de secuencias de dominio variable de inmunoglobulina.
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
EP0438310A1 (en)	1990-01-19	1991-07-24	Merck & Co. Inc.	Method for producing recombinant immunoglobuline
AU3178993A (en)	1991-11-25	1993-06-28	Enzon, Inc.	Multivalent antigen-binding proteins
US6096289A (en)	1992-05-06	2000-08-01	Immunomedics, Inc.	Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
US6005079A (en)	1992-08-21	1999-12-21	Vrije Universiteit Brussels	Immunoglobulins devoid of light chains
ES2162823T5 (es)	1992-08-21	2010-08-09	Vrije Universiteit Brussel	Inmunoglobulinas desprovistas de cadenas ligeras.
AU6796094A (en)	1993-04-29	1994-11-21	Raymond Hamers	Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of (camelidae)
AU6501296A (en)	1995-07-21	1997-02-18	General Hospital Corporation, The	Method and apparatus of enhancing the delivery of a pharmaceutical formulation
US6060284A (en)	1997-07-25	2000-05-09	Schering Corporation	DNA encoding interleukin-B30
AU3170199A (en)	1998-04-14	1999-11-08	Chugai Research Institute For Molecular Medicine, Inc.	Novel cytokine-like protein
US6326482B1 (en)	1999-04-23	2001-12-04	Genentech, Inc.	SH2 domain-containing peptides
DE60041393D1 (de)	1999-03-11	2009-03-05	Schering Corp	Cytokine aus säugetieren, verwandte reagenzien und verfahren
US7090847B1 (en)	1999-09-09	2006-08-15	Schering Corporation	Mammalian cytokines; related reagents and methods
JP4505166B2 (ja)	1999-09-09	2010-07-21	シェーリングコーポレイション	哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
US7422743B2 (en)	2000-05-10	2008-09-09	Schering Corporation	Mammalian receptor protein DCRS5;methods of treatment
AR039067A1 (es)	2001-11-09	2005-02-09	Pfizer Prod Inc	Anticuerpos para cd40
US20040014194A1 (en)	2002-03-27	2004-01-22	Schering Corporation	Beta-secretase crystals and methods for preparing and using the same
US20070134247A9 (en)	2002-04-12	2007-06-14	Ramot At Tel Aviv University Ltd.	Prevention of brain inflammation as a result of induced autoimmune response
DK1576011T3 (da)	2002-10-30	2009-11-30	Genentech Inc	Inhibering af IL-17 produktion
WO2004071517A2 (en)	2003-02-06	2004-08-26	Schering Corporation	Uses of il-23 related reagents
BRPI0408247A (pt)	2003-03-10	2006-03-01	Schering Corp	usos de antagonistas e agonistas de il-23 e reagentes relacionados
US7410483B2 (en)	2003-05-23	2008-08-12	Novare Surgical Systems, Inc.	Hand-actuated device for remote manipulation of a grasping tool
WO2005044853A2 (en)	2003-11-01	2005-05-19	Genentech, Inc.	Anti-vegf antibodies
SI1678314T1 (sl)	2003-10-22	2013-01-31	Keck Graduate Institute	Metode za sintetiziranje heteromultimernih polipeptidov pri kvasovkah s strategijo razmnoĺ˝evanja haploidnih celic
EP1697417A2 (en)	2003-11-07	2006-09-06	Curagen Corporation	Antibodies against secretory leukocyte protease inhibitor
PE20050925A1 (es)	2003-11-10	2005-11-29	Schering Corp	Anticuerpo recombinante humanizado anti-interleuquina 10
EP1766396B1 (en)	2004-06-07	2010-08-11	Ramot at Tel-Aviv University Ltd.	Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
AR049390A1 (es)	2004-06-09	2006-07-26	Wyeth Corp	Anticuerpos contra la interleuquina-13 humana y usos de los mismos
TWI363091B (en) *	2004-12-20	2012-05-01	Schering Corp	Uses of mammalian cytokine; related reagents
JP5174466B2 (ja)	2005-02-08	2013-04-03	ジェンザイム・コーポレーション	ＴＧＦβに対する抗体
SI2452694T1 (sl) *	2005-06-30	2019-05-31	Janssen Biotech, Inc.	Protitelesa proti-IL-23, sestavki in postopki uporabe
BRPI0615018A2 (pt)	2005-08-25	2011-04-26	Lilly Co Eli	anticorpos anti-il-23, ou porção de ligação de antìgeno do mesmo, composição contendo o mesmo e referido uso
EP2354160A1 (en) *	2005-08-31	2011-08-10	Schering Corporation	Engineered anti-IL-23-antibodies
MX2008008621A (es)	2005-12-29	2008-11-27	Centocor Inc	Anticuerpos anti-il-23 humanos, composiciones, metodos y usos.
JP2009540018A (ja)	2006-06-13	2009-11-19	ザイモジェネティクス，インコーポレイテッド	Ｉｌ−１７およびｉｌ−２３アンタゴニストならびにその使用方法
CN101687925B (zh)	2007-02-23	2012-10-31	先灵公司	抗IL-23p19的工程抗体
WO2008103473A1 (en) *	2007-02-23	2008-08-28	Schering Corporation	Engineered anti-il-23p19 antibodies
WO2008134659A2 (en)	2007-04-27	2008-11-06	Zymogenetics, Inc.	Antagonists to il-17a, il-17f, and il-23p19 and methods of use
AR068723A1 (es)	2007-10-05	2009-12-02	Glaxo Group Ltd	Proteina que se une a antigenos que se une a il-23 humana y sus usos
US8975382B2 (en)	2007-11-27	2015-03-10	Ablynx N.V.	Amino acid sequences directed against HER2 and polypeptides comprising the same for the treatment of cancers and/or tumors
WO2009082624A2 (en)	2007-12-10	2009-07-02	Zymogenetics, Inc.	Antagonists of il-17a, il-17f, and il-23 and methods of using the same

2008
- 2008-02-21 CN CN2008800131689A patent/CN101687925B/zh active Active
- 2008-02-21 HU HUE11172014A patent/HUE042172T2/hu unknown
- 2008-02-21 ES ES11172014T patent/ES2708988T3/es active Active
- 2008-02-21 MX MX2009009079A patent/MX2009009079A/es active IP Right Grant
- 2008-02-21 JP JP2009550920A patent/JP2010518856A/ja active Pending
- 2008-02-21 PT PT08714211T patent/PT2059534E/pt unknown
- 2008-02-21 CA CA2678749A patent/CA2678749C/en active Active
- 2008-02-21 PL PL11172014T patent/PL2426144T3/pl unknown
- 2008-02-21 TR TR2018/21029T patent/TR201821029T4/tr unknown
- 2008-02-21 SI SI200832032T patent/SI2426144T1/sl unknown
- 2008-02-21 AU AU2008218968A patent/AU2008218968B2/en active Active
- 2008-02-21 EP EP08714211A patent/EP2059534B1/en active Active
- 2008-02-21 DK DK11172014.0T patent/DK2426144T3/en active
- 2008-02-21 BR BRPI0807710-0A patent/BRPI0807710B1/pt active IP Right Grant
- 2008-02-21 EP EP11172014.0A patent/EP2426144B1/en active Active
- 2008-02-21 PL PL08714211T patent/PL2059534T3/pl unknown
- 2008-02-21 AT AT08714211T patent/ATE554791T1/de active
- 2008-02-21 RS RS20181559A patent/RS58098B1/sr unknown
- 2008-02-21 AR ARP080100715A patent/AR065420A1/es active IP Right Grant
- 2008-02-21 US US12/526,543 patent/US8293883B2/en active Active
- 2008-02-21 NZ NZ579158A patent/NZ579158A/en unknown
- 2008-02-21 SI SI200830700T patent/SI2059534T1/sl unknown
- 2008-02-21 ES ES08714211T patent/ES2388837T3/es active Active
- 2008-02-21 DK DK08714211.3T patent/DK2059534T3/da active
- 2008-02-21 LT LTEP11172014.0T patent/LT2426144T/lt unknown
- 2008-02-21 PT PT11172014T patent/PT2426144T/pt unknown
- 2008-02-21 KR KR1020097019349A patent/KR101520110B1/ko active IP Right Grant
- 2008-02-21 RS RS20120308A patent/RS52345B/en unknown
- 2008-02-21 WO PCT/US2008/002333 patent/WO2008103432A1/en active Application Filing
2009
- 2009-06-11 HK HK09105259.6A patent/HK1127864A1/xx unknown
- 2009-08-23 IL IL200560A patent/IL200560A/en active Protection Beyond IP Right Term
- 2009-09-08 ZA ZA200906224A patent/ZA200906224B/xx unknown
2011
- 2011-02-21 US US13/031,544 patent/US8404813B2/en active Active
2012
- 2012-03-07 JP JP2012050650A patent/JP5014521B2/ja active Active
- 2012-07-10 JP JP2012154567A patent/JP2012228259A/ja active Pending
- 2012-07-20 CY CY20121100644T patent/CY1112912T1/el unknown
- 2012-07-24 HR HRP20120611AT patent/HRP20120611T1/hr unknown
- 2012-12-17 US US13/717,131 patent/US9809648B2/en active Active
2014
- 2014-02-27 JP JP2014036399A patent/JP6054898B2/ja active Active
2016
- 2016-10-27 JP JP2016210272A patent/JP2017060482A/ja not_active Withdrawn
2018
- 2018-11-09 HU HUS1800045C patent/HUS1800045I1/hu unknown
- 2018-11-13 LU LU00092C patent/LUC00092I2/fr unknown
- 2018-11-15 NO NO2018040C patent/NO2018040I1/no unknown
- 2018-12-04 FR FR18C1051C patent/FR18C1051I2/fr active Active
- 2018-12-05 NL NL300959C patent/NL300959I2/en unknown
- 2018-12-13 LT LTPA2018015C patent/LTC2059534I2/lt unknown
- 2018-12-21 HR HRP20182174TT patent/HRP20182174T1/hr unknown
2019
- 2019-01-14 CY CY2019004C patent/CY2019004I2/el unknown
- 2019-01-21 CY CY20191100082T patent/CY1121327T1/el unknown

Also Published As

Publication number	Publication date
CY1121327T1 (el)	2020-05-29
KR101520110B1 (ko)	2015-05-18
LTC2059534I2 (lt)	2019-10-10
US20130122009A1 (en)	2013-05-16
NL300959I2 (en)	2019-01-15
US8404813B2 (en)	2013-03-26
AU2008218968A1 (en)	2008-08-28
JP2017060482A (ja)	2017-03-30
AR065420A1 (es)	2009-06-03
AU2008218968B2 (en)	2013-10-17
ES2708988T3 (es)	2019-04-12
PL2059534T3 (pl)	2012-09-28
HUS1800045I1 (hu)	2018-12-28
JP2012228259A (ja)	2012-11-22
EP2426144A1 (en)	2012-03-07
CN101687925A (zh)	2010-03-31
ATE554791T1 (de)	2012-05-15
IL200560A (en)	2013-11-28
CN101687925B (zh)	2012-10-31
DK2059534T3 (da)	2012-08-06
HRP20182174T1 (hr)	2019-02-22
HRP20120611T1 (hr)	2012-10-31
CA2678749A1 (en)	2008-08-28
US9809648B2 (en)	2017-11-07
US20100272731A1 (en)	2010-10-28
WO2008103432A1 (en)	2008-08-28
LTPA2018015I1 (lt)	2019-01-10
FR18C1051I2 (fr)	2019-12-27
DK2426144T3 (en)	2019-01-07
NO2018040I1 (no)	2018-11-15
MX2009009079A (es)	2009-08-31
CA2678749C (en)	2018-03-13
CY1112912T1 (el)	2016-04-13
JP2014128278A (ja)	2014-07-10
JP5014521B2 (ja)	2012-08-29
RS58098B1 (sr)	2019-02-28
ZA200906224B (en)	2010-07-28
KR20090114459A (ko)	2009-11-03
BRPI0807710A2 (pt)	2014-05-27
ES2388837T3 (es)	2012-10-19
HUE042172T2 (hu)	2019-06-28
RS52345B (en)	2012-12-31
EP2426144B1 (en)	2018-10-31
TR201821029T4 (tr)	2019-01-21
LT2426144T (lt)	2018-12-10
US20110142853A1 (en)	2011-06-16
FR18C1051I1 (el)	2019-02-15
JP2010518856A (ja)	2010-06-03
EP2059534B1 (en)	2012-04-25
CY2019004I2 (el)	2019-11-27
SI2426144T1 (sl)	2019-02-28
PL2426144T3 (pl)	2019-05-31
SI2059534T1 (sl)	2012-08-31
NZ579158A (en)	2012-01-12
LUC00092I2 (el)	2019-12-24
JP2012135319A (ja)	2012-07-19
HK1127864A1 (el)	2009-10-09
EP2059534A1 (en)	2009-05-20
PT2059534E (pt)	2012-07-17
BRPI0807710A8 (pt)	2016-02-10
BRPI0807710B1 (pt)	2021-12-14
LUC00092I1 (el)	2018-11-15
JP6054898B2 (ja)	2016-12-27
US8293883B2 (en)	2012-10-23
PT2426144T (pt)	2019-02-06
IL200560A0 (en)	2010-05-17

Publication	Publication Date	Title
CY2019004I1 (el)	2019-11-27	Τροποποιημενα αντισωματα αντι-ιl-23ρ19
BRPI0906877A2 (pt)	2015-07-28	Anticorpos anti-trkb aperfeiçoados
BRPI0907237A2 (pt)	2015-07-14	Anticorpo anti-cldn6
BRPI0809677A2 (pt)	2014-10-07	Anticorpos anti-ige
EP2211903A4 (en)	2011-07-06	CLL-1 ANTIBODY
BRPI0819165A2 (pt)	2015-06-23	Anticorpos anti-vegf
DK2131860T3 (da)	2014-01-13	Anti-sclerostin-antistoffer
BRPI0820073A2 (pt)	2015-06-23	Anticorpos anti-axl
DK3118221T3 (da)	2019-09-23	Proteiner
EP2337798A4 (en)	2012-10-24	SPECIFIC ANTIBODIES OF THE ASB
EP2185560A4 (en)	2011-10-05	HETEROARYLAMIDE ANALOGS
BRPI0807991A2 (pt)	2014-06-17	Anticorpos anti-il-23r elaborados.
EP2188984A4 (en)	2010-11-24	PREPARATION OF TRANSPORT FLOW PACKAGE (TS)
EP2172483A4 (en)	2010-08-04	ANTI-MUC17 ANTIBODY
BRPI0815567A2 (pt)	2015-02-18	Anticorpos híbridos antialfa v-integrina projetados
DE112008003636A5 (de)	2010-10-21	Mehrzuggruppierer
FI20075610A0 (fi)	2007-09-05	Rikastepoltin
BRPI0817427A2 (pt)	2015-06-16	Anticorpo anti-bst2
BRPI0814971A2 (pt)	2015-02-03	Proteína
EP2207803A4 (en)	2010-11-24	Cd9-specific human antibodies
BRPI0909633A2 (pt)	2015-09-22	anticorpos anti-tyrp1
BRPI0815547A2 (pt)	2015-02-10	Depsipeptídeos cícliocos
FI20075277A0 (fi)	2007-04-20	Radiaalisiipipyörä
DE602008004695D1 (de)	2011-03-10	Katalysatorträgerwabe
EP2212431A4 (en)	2011-05-11	ANTIBODY AGAINST IREM-1